Phase II Multi-center Study of Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Oct 2017 Status changed from not yet recruiting to recruiting.
- 05 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Oct 2017.
- 10 Aug 2017 New trial record